PanTera nv

PanTera wants to bring new hope to cancer patients by enabling the widespread application of radiopharmaceuticals for precision treatment of tumors.

Our core belief is that these powerful medical tools deserve a central role in oncology for their potential to treat cancers effectively while preserving patient's quality of life. Our focus is on the radiotheranostics field, which facilitates patient-tailored optimization of treatment by tracking the distribution of therapeutic agents in the body. This cutting-edge approach minimizes patient side-effects while enhancing treatment efficacy.

Our vision is to make such personalized nuclear medicine treatments a reality, making them widely available and affordable. To realize this vision, we are establishing a state-of-the-art production facility for actinium-225 (Ac-225) in Mol, Belgium. Our unique production process, employing the photonuclear or ‘gamma’ route, transforms Radium-226 (226Ra) into 225Ra, which in turn decays into Ac-225. This high-purity Ac-225 is then supplied as an Active Product Ingredient (API) to the global pharmaceutical market.

In addition to ensuring quality, we prioritize sustainability. The radium in our process is recycled and reused, emphasizing our commitment to environmentally friendly practices. At PanTera, we are not only supporting the development of the next generation of cancer treatments but also fostering a future where personalized nuclear medicine is the norm.